Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Kovack Advisors Inc.

Kovack Advisors Inc. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,495 shares of the biopharmaceutical company’s stock after purchasing an additional 685 shares during the period. Kovack Advisors Inc.’s holdings in Gilead Sciences were worth $850,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of GILD. Clearbridge Investments LLC boosted its stake in shares of Gilead Sciences by 179.0% during the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after purchasing an additional 2,915,141 shares during the last quarter. abrdn plc lifted its holdings in shares of Gilead Sciences by 89.0% during the 4th quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after acquiring an additional 1,772,887 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $133,584,000. AEGON ASSET MANAGEMENT UK Plc purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $63,971,000. Finally, Bailard Inc. lifted its holdings in shares of Gilead Sciences by 9,100.7% during the 3rd quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock worth $54,133,000 after acquiring an additional 714,494 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

GILD opened at $65.42 on Friday. The firm has a market capitalization of $81.45 billion, a P/E ratio of 181.72, a P/E/G ratio of 1.17 and a beta of 0.19. The firm’s 50 day moving average is $71.28 and its 200-day moving average is $76.25. Gilead Sciences, Inc. has a 52-week low of $64.63 and a 52-week high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.37 earnings per share. Analysts expect that Gilead Sciences, Inc. will post 3.82 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is currently 855.56%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Barclays cut their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Royal Bank of Canada cut their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a report on Friday. UBS Group cut their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Mizuho cut their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Finally, StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $83.87.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.